|Mr. Nikolaj SÃ¸rensen||Pres & CEO||N/A||N/A||1972|
|Mr. Joseph DeFeo||Exec. VP & CFO||N/A||N/A||1961|
|Ms. Cecilia Coupland||VP & Head of Operations||N/A||N/A||1976|
|Lena Wange||Head of Investor Relations & Communications Director||N/A||N/A||N/A|
|Dr. Michael Sumner||Chief Medical Officer||N/A||N/A||1965|
|Mr. Johannes Doll||Exec. VP & Chief Commercial Officer||N/A||N/A||1981|
|Mr. Robert RÃ¶nn||VP and Head of R&D||N/A||N/A||1976|
|Mr. Dennis Urbaniak||Exec. VP of Digital Therapeutics||N/A||N/A||1969|
|Mr. Robert A. Deluca||Pres of Orexo US Inc||N/A||N/A||1961|
|Mr. Jesper Lind||Advisor||N/A||N/A||1960|
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Orexo AB (publ)’s ISS Governance QualityScore as of July 1, 2021 is 2. The pillar scores are Audit: 8; Board: 1; Shareholder Rights: 1; Compensation: 6.